TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Central Foveal Thickness (CFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores at rest and on movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of analgesic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful rate of 3-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in nail length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of proinflammatory cytokines (IL-6 and IL-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CVD risk
Endpoint domain: Mortality/survival
Primary endpoint: completeness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life response rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Gastrointestinal Symptom Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total Psychological General Well‐Being score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bending strength of BioHPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary block success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary catheter failure
Endpoint domain: Adverse events/effects
Primary endpoint: perfusion deficit in cerebral microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hip posture improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder posture improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative excess weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasminogen activator inhibitor-1 (PAI-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eroded surface in cancellous bone (ES/BS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone formation indices (osteoid surface, OS/BS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone formation indices (mineralising surface, MS/BS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of applications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent HBDT accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year Disease-Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: 3-year Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Grade of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: chest compression depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: range of trunk lateral-flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postanesthesia pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difference of the postanesthesia score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients failing on three or more criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in appropriate social behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Increase in social cognitive skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decrease in aggressive behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital admission for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: survival without admission due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: T cell and antibody response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude of interferon gamma (IFN‐γ) ELISPOT responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of the vaccines
Endpoint domain: Adverse events/effects
Primary endpoint: Number of times a review for misfit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bleeding recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variceal eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cost of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per life-year gained (LYG)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Major adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric hypersensitivity to distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Defective gastric relaxatory responses to duodenal distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nasal and ocular symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to behavior change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tiselius CRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle spasm and joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence of any deep vein thrombosis, non‐fatal pulmonary embolism, and all‐cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Maximum relaxation to ACh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum contractile response to endothelin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Response to thromboxane agonist U46619
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: late lumen loss in-stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolongation of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Apgar score of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Seroprotective antibody concentrations/titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of local injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Driving ability with visual field defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in prevention of mother-to-child transmission services
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Persistence of depressive disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tolerance for VCUG procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tolerability of recombinant FXIII
Endpoint domain: Adverse events/effects
Primary endpoint: plasma ACTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CSF DHA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF-to-plasma DHA ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ApoB-100 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean in-stent diameter (MLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for target vessel revascularization (TVR)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Eye pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Escape medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to pain cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross and fine motor functions improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative complications within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Isovolumetric relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E/E' ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean duration of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: level of erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Neurodevelopmental childhood outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood to bring child to provider
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Negative reactions to dismissive scenario
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in glycated hemoglobin (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients at target A1C <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Documented symptomatic hypoglycemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: AR mRNA expression in GCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSHR mRNA expression in GCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause 28-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: disease activity indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma and urine hesperetin-glucuronide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TUG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UST score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LV ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Technique survival rate
Endpoint domain: Mortality/survival
Primary endpoint: bond durability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall number of positive dietary changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAG repeat distribution in AR gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TA repeat distribution in ER gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of stone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of residents feeling highly motivated
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in penile length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in penile diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in glans diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of spontaneous recovery of heart beat after aorta unclamping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of TNF-α and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: abstinence from opioids, stimulants, or heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leukopenia ≥grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Dopamine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: G-CSF plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD64 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma ANP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma cGMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lesion clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Median daily DEHP intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of subjects exceeding RfD value
Endpoint domain: Adverse events/effects
Primary endpoint: mean number of persisting sites with probing depth >4 mm and bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical parameters (erythrocyte sedimentation rate, C reactive protein, swollen and tender joints, radiological progression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spinal height increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting glucagon levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postprandial glucagon levels (4-hour AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in migraine headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hour headache relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg wound infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Healing process (aspect of tonsillar fossa on the 10th day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum protein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 6-min-walk-test (6MWT) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total amino acid response (AUC for 8 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of cryptococcal disease
Endpoint domain: Mortality/survival
Primary endpoint: Time to first episode of candidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine reoperations
Endpoint domain: Adverse events/effects
Primary endpoint: Severe World Health Organization Grade 3 and 4 events
Endpoint domain: Adverse events/effects
Primary endpoint: subsequent spontaneous preterm birth
Endpoint domain: Mortality/survival
Primary endpoint: mean delivery gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: mean birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Physical Functioning (PF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean elimination half-life of gadobutrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean recovery of gadobutrol in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: duration of diarrhoea after randomisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDRS-R total score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening of suicidal ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Activities of Daily Living (ADLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental Activities of Daily Living (IADLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum urea nitrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nutritional status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global ratings of acceptability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: speed gain at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention of acquired skill at day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: down-regulation of H-reflex amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Twelve-month total body weight loss (TBWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PORPUS-U utility scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Onset of End-Stage Renal Disease (ESRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of sexual concerns reported
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity for the diagnosis of HGD/EC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value (PPV) for HGD/EC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of CD4 and CD8 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean dose of levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of daily levodopa doses needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of additional dopaminergic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain intensity and pain relief scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chinese medical syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient number with normal WBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient number with normal chest X ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful arterial catheterization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in antimalarial prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Malaria parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Symptoms reported by children
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in efficacy measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of regression of coronary artery disease (CAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of progression of coronary artery disease (CAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death from cardiovascular causes at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Worsening heart failure at 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet aggregation response to ADP and collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline in GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to resumption of spontaneous breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral ultrasound anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive Toxoplasma gondii polymerase chain reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes